Prosecution Insights
Last updated: November 04, 2026
Application No. 18/704,457

METHODS OF USING CYCLOSPORINE A OPHTHALMIC GEL IN TREATING MODERATE-TO-SEVERE DRY EYE DISEASE

Non-Final OA §103§112
Filed
Apr 25, 2024
Priority
Oct 26, 2021 — CN PCT/CN2021/126462 +1 more
Examiner
BEANE, RANDALL L
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd.
OA Round
1 (Non-Final)
33%
Grant Probability
At Risk
1-2
OA Rounds
9m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
151 granted / 459 resolved
-27.1% vs TC avg
Strong +36% interview lift
Without
With
+36.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
58 currently pending
Career history
524
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
31.5%
-8.5% vs TC avg
§102
14.9%
-25.1% vs TC avg
§112
32.9%
-7.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 459 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 1-2, 4-11, and 13-14 are pending and presently examined. Election/Restrictions Applicant's election with traverse of subgenus of patentably indistinct species consistent with Example 71 in the reply filed on 9/07/2026 is acknowledged. The traversal is on the grounds that the lack of unity established in the Requirement mailed 7/08/2026 in view of the claims pending 12/21/2024, does not establish lack of unity of invention of the newly amended claims as filed 9/07/2026. This is not found persuasive because there is no evidence presented that the lack of unity was not properly made at the time in view of the previously pending claims; furthermore, upon review the newly amended claims continue to lack inventive step and/or novelty in view of the prior art, which is applied below. The requirement is still deemed proper and is therefore made FINAL. The election of a subgenus of patentably indistinct species consistent with Example 7 is understood as follows: Claim 1 was amended in the reply filed 9/07/2026 to read upon administration of a subgenus of patentably indistinct formulations of cyclosporine A ophthalmic gels defined at paragraph [0067] of the Specification (see, e.g., Spec. filed 4/25/2024 at ¶[0067]2; recited at amended claim 1). Notably, Example 7 is understood to be a method of treating moderate to severe tear deficiency in a human subject, by administering “0.3g:0.15 mg”3 cyclosporine gel once daily for 84±6 days following a wash out period of 14 days (understood to be 0.05% per ¶[00l75] and [00191]), wherein VAS score, BUT determination, corneal staining, ICSS scoring, and Schirmer test is performed before, during, and after administration to monitor progress (see, e.g., Spec. filed 4/25/2024 at ¶¶[00l76]-[00522]; see esp. id. at ¶¶[00189], [00193], [00260], [00285]-[00290]). Applicant identified that the originally elected species read upon claims 1-2, 4-7, 9-11, and 13-14 (see Reply filed 9/07/2026 at 5-6). Following extensive search and examination, the originally elected species has been deemed anticipated and/or obvious in view of the prior art as applied below. Per MPEP § 803.02(III)(A), Following election, the Markush claim will be examined fully with respect to the elected species and further to the extent necessary to determine patentability. Note that where a claim reads on multiple species, only one species needs to be taught or suggested by the prior art in order for the claim to be anticipated or rendered obvious... If the Markush claim is not allowable, the provisional election will be given effect and examination will be limited to the Markush claim and claims to the elected species, with claims drawn to species patentably distinct from the elected species held withdrawn from further consideration. Accordingly, claims 1-2, 4-11, and 13-14 are rejected in view of the originally elected species and claims that do not read upon the originally elected species are withdrawn. Currently, no claims are withdrawn. Claims 1-2, 4-11, and 13-14 are presently considered. Denial of Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, PCT/CN2021/126462 (filed 10/26/2021) fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. The MPEP states that "[w]hile there is no in haec verba requirment, . . . . claim limitations must be supported in the specification through express, implicit, or inherent disclosure." See MPEP § 2163. Lack of Express Support Instant claim 1, as amended in the Reply filed 9/07/2026, is representative of the pending claim scope. Amended claim 1 does not literally appear in the priority document, and therefore the claims lack literal support in PCT/CN2021/126462. More specifically, PCT/CN2021/126462 does not recite all components and percentages now recited at instant claim 1 (e.g., “0.1-10 wt% nonionic surfactant” and other limitations are literally absent from the priority document). Accordingly, the provisional fails to provide literal support for the pending claim scope that is synonymous or equivalent in scope. Lack of Implicit or Inherent Support The MPEP states that "[w]hile there is no in haec verba requirment, . . . . claim limitations must be supported in the specification through express, implicit, or inherent disclosure." See MPEP § 2163. In the absence of express support, the relevant issue is whether or not the claimed invention is supported by Pro’231 through implicit or inherent disclosures. Upon review, zero inherent or implicit support commensurate in scope with the metes and bounds of the instant claims is found in the priority document, at least because the limitations set forth at amended claim 1 are literally, implicitly, and inherently absent from the priority document. Presumably, the closest disclosure appears at paragraph [28] of the priority document, which references Chinese Patent Number ZL201410033737.3, which was identified as published as CN103735495B (see, e.g., PCT/CN2021/126462 at ¶[28]). This is insufficient because, at best, the reference would be an improper attempt at incorporation by reference because the language at 37 C.F.R. 157(c) is absent, and such subject matter is “essential material” and does not satisfy 37 C.F.R. 157(d) (see, e.g., MPEP § 608.01(p)). According, the claim language presently claimed is not supported by the priority document by synonymous or equivalent language. Accordingly, PCT/CN2021/126462 fails to provide implicit or inherent support for the pending claim scope that is synonymous or equivalent in scope, or otherwise commensurate in scope with the pending claims. Conclusion Accordingly, priority to PCT/CN2021/126462 (filed 10/26/2021) is denied for claim 1 and all of the dependents of that claim; these claims have been accorded with a priority date of 10/26/2022, which corresponds to the filing date of the 371 of PCT/CN2022/127767. Information Disclosure Statement No IDS has been filed on record. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. It is noted that the duty of disclosure, candor, and good faith is applicable to named inventors, each attorney or agent that prepares or prosecutes, and all persons substantively involved in the preparation or prosecution of the application, and who are associated with the inventor, the applicant, an assignee, or anyone to whom there is an obligation to assign the application (see, e.g., 37 C.F.R. 1.63(c) and 37 C.F.R. 1.56). Here, Examiner notes that multiple references, including at least CN103735495 (April 23, 2014; Chinese) and NCT03676335, were known to one or more named inventors, but were not placed on record. Drawings The drawings are objected to because Figure 13, as filed 4/25/2024 is not fully legible. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Specification The disclosure is objected to because of the following informalities: In the Specification filed 4/25/2024, the structure shown at paragraph [0089] is illegible. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Appropriate correction is required. Claim Objections Claims 5-8 and 10 are objected to because of the following informalities: At claims 5 and 8, the article “the” should be used rather than “an” in “an effective amount”. At claims 6-7, the article “the” should be used rather than “a” at “a concentration of cyclosporine A”. At claim 7, the spacing is incorrect at “0.05%by”. At claim 10, the article “the” should be used rather than “a” at “a time window”. Appropriate correction is required. Claim Interpretation For purposes of examination, the claim scope has been interpreted as set forth below per the guidance set forth at MPEP § 2111. If Applicant disputes any interpretation, Applicant is invited to unambiguously identify any alleged misinterpretations or specialized definitions in the subsequent response to the instant action. Applicant is advised that a specialized definition should be properly supported and specifically identified (see, e.g., MPEP § 2111.01(IV), describing how Applicant may act as their own lexicographer). “Comprising” is an open-ended transitional term (see, e.g., MPEP § 2111.03(I)), wherein additional steps or components are not excluded. However, “‘[c]omprising’ is a term of art used in claim language which means that the named elements are essential” (see, e.g., id.; see also Genentech, Inc. v. Chiron Corp., 112 F.3d 495, 501, 42 USPQ2d 1608, 1613 (Fed. Cir. 1997)). Amended claim 1, as filed 9/07/2026, is representative of the pending claim scope, which is directed to a method of treating moderate to severe dry eye disease in a subject in need thereof, by administering to the subject an “effective amount” of a composition comprising 0.001-1 wt% cyclosporine A, 0.1-10 wt% nonionic surfactant, 0.01-5 wt% of either sodium carboxymethyl cellulose or carbomer, 2-30 wt% wetting agent, water in an unspecified amount, and a pH adjusting agent sufficient so that the final pH of the composition is 5.0-8.0 (see, e.g., amended claim 1 as filed 9/07/2026). These limitations are understood to be fully satisfied by “Hy Cyclosporine A is interpreted consistent with the original disclosure (see, e.g., Spec. filed 4/25/2024 at ¶¶[0063]-[0064]) and the prior art. This compound is also known in the art as Ciclosporin and cyclosporin. It has a CAS Number of 59865-13-3, and a PubChem CID of 5284373. “Nonionic-surfactant” is recited only at paragraph [0067] of the Specification (see, e.g., Spec. filed 4/25/2024 at ¶[0067]), and is not defined or exemplified. Accordingly, the term is reasonably inferred to include any art-recognized “nonionic-surfactant”, which includes polyethylene glycols, propylene glycols, glyceryl monostearate, povidone, Tween 80, and polyoxyethylene castor oil (see, e.g., Machine Translation of CN1037354954 at ¶[0013]). “Aqueous gel substrate” is defined in amended claim 1 to be either sodium carboxymethyl cellulose or carbomer (see, e.g., amended claim 1 as filed 9/07/2026; see, e.g., Spec. filed 4/25/2024 at ¶¶[0067], [00162], [00196], [00477]). “Wetting agent” is recited only at paragraph [0067] of the Specification (see, e.g., Spec. filed 4/25/2024 at ¶[0067]), and is not defined or exemplified. Accordingly, the term is given the broadest reasonable interpretation and includes any “wetting agent” known in the prior art, which includes at least propylene glycol and/or glycerin (see, e.g., Machine Translation of CN103735495 at ¶[0015]). “pH adjusting agent” is recited only at paragraph [0067] of the Specification (see, e.g., Spec. filed 4/25/2024 at ¶[0067]), and is not defined or exemplified. Accordingly, the term is given the broadest reasonable interpretation and includes any “pH adjusting agent” known in the prior art, which includes at least sodium hydroxide, sodium bicarbonate, and hydrochloric acid (see, e.g., Machine Translation of CN103735495 at ¶[0049]). “About” is understood to mean ± 20% of a recited range (see, e.g., Spec. filed 4/25/2024 at ¶[0042]). Accordingly, “about 0.05% to about 0.1% by weight” at claim 6 is understood to include the range of 0.05%±20% to 0.1%±20%, which is “0.01% to 0.12% by weight”. At claim 7, the phrase “is about 0.05% by weight”, is understood to mean 0.05%±20%, which is the range 0.01% to 0.06%. At claim 8, the phrase “about 0.025 mg” is understood to mean 0.025±20%, which is the range 0.005 to 0.03 mg. “Treat”, “treating”, or “treatment” is interpreted consistent with the original disclosure (see, e.g., Spec. filed 4/25/2024 at ¶[0044]). “Administer”, “administering”, or “administration” is interpreted consistent with the original disclosure (see, e.g., Spec. filed 4/25/2024 at ¶[0044]). The phrase “administered every night before the subject goes to bed” does not provide a specific window of time (i.e., 1 second, 1 minute, 1 hour, etc. “before . . . bed”). In view of the specification, the timeframe is understood to include treatment at least within two hours before a subject goes to bed (see, e.g., Spec. filed 4/25/2024 at ¶[0073]). At claim 11, the phrase “at day 84 since the administrating starts, the subject's ICSS drops by at least l point from the subject's ICSS before said administering” is understood to recite an intended and expected result fully satisfied by the performance of the active method steps set forth in the bodies of claims 1 and 2. Per MPEP § 2111.04(I), “Claim scope is not limited by claim language that . . . . does not require steps to be performed, or by claim language that does not limit a claim to a particular structure”, and further states that a “whereby clause” in a claim “is not given weight when it simply expresses the intended result of a process step positively recited”. Here, the “wherein” clause does not unambiguously correspond to a clear structure/function relationship in the original disclosure, and therefore is not a functional limitation. Rather, the “wherein” clause is understood to merely recite an intended or expected result fully satisfied by the positively recited steps and/or structures set forth in the body of the claim. Therefore, the “wherein” clause of claim 11 is understood to be fully satisfied by all prior art embodiments that satisfy claims 1 and 2. If this is incorrect, and claim 11 is further limiting, then Applicant should identify all species of methods within the scope of claims 1-2 that are not fully enabling for the limitation of claim 11. At claims 13-14, the claims require that “onset of efficacy starts no more than [14 or 30] days as measured by corneal fluorescein staining since first administration….”. This limitation is understood to require corneal fluorescein staining steps to occur “no more than [30 or 14] days” after administration commences. However, the portion regarding “onset of efficacy” is understood to At claims 13-14, "onset of efficacy" is interpreted consistent with the specification, and is understood to be interchangeable with "onset of action" and "onset of effect," wherein "onset of efficacy" refers to the first day on which the proportion of subjects with ICSS decreased by ≥ 1 point was significantly greater in the cyclosporine A ophthalmic gel group than in the vehicle group (p<0.05) (see, e.g., Spec. filed 4/25/2024 at ¶¶[0080]-[0082]). This limitation is understood to be satisfied for all embodiments that satisfy the positively recited limitations of instant claim 1; if this is incorrect, Applicant should identify, with specificity, all species of methods of claim 1 that are not fully enabling for the limitations at claims 13-14. Additional claim interpretations are provided below. Claim Rejections Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 5, 11, and 13-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 2 recites “Eye dryness score (EDS) ≥ 40 (visual analogue scale [VAS] of 0-100 points)”, which renders the claim scope indefinite because it is unclear if the parenthetical is redefining what constitutes an EDS ≥ 40, or if the parenthetical requires a separate and distinct test. Clarification is required. For purposes of applying prior art, art teaching EDS, or both EDS and VAS is understood to read upon the instant claims. Claim 2 recites that “the subject is characterized in….”, but claim 2 depends from a treatment method, and therefore a subject exists before, during, and after treatment commences, wherein such characterizations presumably alter if the treatment is successful. Accordingly, the claim scope and required active method steps are unclear because it is unknown if such “characterization” occurs once or multiple times, and if it occurs before treatment, during treatment, after treatment, or a combination thereof. Clarification is required. For purposes of applying prior art, the characterization step is understood to occur at least once, at any time before, during, or after the cessation of treatment. Claim 5 recites that an “effective amount” is “one drop”, which renders the claim scope indefinite. The term “drop” in claim 5 is a relative term which renders the claim indefinite. The term “drop” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention because the volume of “one drop” presumably depends upon the exact formulation utilized, viscosity of a solution or gel, temperature, etc. For purposes of applying prior art, “one drop” is understood to be a volume sufficient to deliver “about 0.025 mg cyclosporine A” consistent with instant claim 8. Claim 11 recites “at day 84 since the administrating starts”, which renders the claim scope indefinite because “the administrating” appears to refer to an ongoing process, but claim 11 depends from claims 1-2, and claim 1 recites a single administration, and fails to recite additional, ongoing steps. This creates confusion regarding the literal and implied limitations and the metes and bounds of the pending claim scope. Accordingly, claim 11 is indefinite because claim 11 presumably should either read “after 84 days following the administration of cyclosporine A ophthalmic gel” (i.e., consistent with the single administration of claim 1), or otherwise recite “wherein an effective amount of cyclosporine A ophthalmic gel is administered to a subject once daily; and after 84 days of treatment….” (i.e., adding the steps of repeated administration for a defined time period). Accordingly, clarification is required. For purposes of applying prior art, claim 11 is understood to literally require at least one administration of cyclosporine A ophthalmic gel” (i.e., consistent with the single administration of claim 1), but may include daily administration. The remaining interpretation of claim 11 has been set forth in the claim interpretation section above, and the claim is interpreted consistent with MPEP § 2111.04(I). Claims 13 and 14 depend from claim 1, but recite a “in a treatment period”, which renders the claim scope indefinite because claim 1 does not recite a time period or require repeated administrations. In addition, “treatment period” is undefined on record. Accordingly, as presently drafted, it is unclear if claims 13 and 14 merely recite an intended or expected result, fully satisfied by any method satisfying the positively recited method steps set forth in the body of instant claim 1 (i.e., a single explicit administration occurring 14 or 30 days earlier) (see, e.g., MPEP § 2111.04(I)5), or if claims 13 and 14 are intended to imply a “treatment period” involving multiple administrations (e.g., once daily administrations). Clarification is required and limitations should be explicit in the pending claim scope. For purposes of applying prior art, claims 13 and 14 are understood broadly to literally be satisfied by the treatment steps set forth in the body of instant claim 1, and also broadly understood to be satisfied by the treatment steps set forth in dependent claim 4 (i.e., once daily administration). Examiner notes that the limitation of claim 4 presumably should be recited at claim 1. Claim 11 depends directly from an indefinite claim, and fails to clarify the indefiniteness of the claim upon which it depends. Accordingly, claim 11 is rejected as indefinite for the reasons applied to the claim upon which it depends. Claims 2, 5, 11, and 13-14 are rejected. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-2, 4-11, and 13-14 are rejected under 35 U.S.C. 103 as being unpatentable over WO2006/0395586 in view of CN103735495 (April 23, 2014; Chinese) as evidenced by Machine Translation of CN1037354957, and in view of NCT036763358. Claim interpretation: The applicable claim interpretation has been set forth in a preceding section above, and those interpretations are incorporated into the instant rejection. Additional claim interpretations are set forth below. Regarding instant claims, generally, WO’558 establishes that methods of treating moderate to severe dry eye have by administering cyclosporine A ophthalmic gel formulations to patients in need thereof, have been known since at least circa 2006 (see, e.g., WO’558 at title, abs, claims, ¶¶[0001]-[0007], passim). Regarding instant claims 1, 6-8, and specific gel formulations, WO’558 identifies that ocular gels useful for such treatments were understood to comprise cyclosporine A, water, non-ionic hydrophilic emulsifiers (surfactants), wetting agents, sodium carboxymethyl cellulose, pH buffering agents (see, e.g., WO’558 at claims 1-7, 21-22, ¶¶[0003], [0032], [0071], [0077]), wherein pH could be adjusted from “about 6.0 to about 9.0”, wherein a pH of 7.4 was understood to match the pH of tear fluid (see, e.g., WO’558 at ¶¶[0043], [0091]). Regarding instant claims 1 and administration, WO’558 identifies that such formulations could be administered to patients to treat keratoconjunctivitis sicca (see, e.g., WO’558 at claims 21-22), wherein an artisan would understand that “keratoconjunctivitis sicca” is the medical term for Dry eye disease (DED), and would appreciate that “administration” covers ocular administration to an ocular environment, such as tear fluid (see, e.g., WO’558 at ¶¶[0013], [0027], [0067]). Regarding instant claims 1, 5-8, and a “therapeutically effective amount”, WO’558 identifies that a therapeutically effective amount of cyclosporine A may be “about 0.001 mg/kg to about 10 mg/kg” (see, e.g., WO’558 at ¶¶[0012]-[0013]), wherein cyclosporine A is present at “about 0.005% to about 0.50% CSA (w/w)” (see id; see also MPEP § 2144.05(I), noting that “where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists”). Regarding instant claims 1, 4-5, 9, 11, 13-14, and efficacious dosing frequency permitting treatment of keratoconjunctivitis sicca, WO’558 identifies that patient parameters and severity of disease impact dosing regimens, and that dosing regimens may be optimized (see, e.g., WO’558 at ¶¶[0006]-[0007], [0060]-[0061]), and that dosing frequency, including in combination with other agents, may include administering the agents at time points that vary from “about 15 minutes” to “24 hours”, to even “1 week” in time (see, e.g., WO’558 at ¶¶[0006]-[0007], [0060]-[0061]). Accordingly, in view of WO’558, an artisan would readily appreciate that dosing frequency could vary substantially, and was an optimizable parameter (see id; see also MPEP § 2144.05(I), noting that “where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists”). Regarding instant claim 10 and the administration of additional drugs with a time window of “no less than 5 minutes”, WO’558 identifies that combination therapy with additional drugs had already been contemplated in view of the prior art, and that delivery of combination therapy agents could be performed at different time points varying by “about 15 minutes” up to even “1 week in time” (see, e.g., WO’558 at ¶¶[0059]-[0063]). In sum, methods of treating dry eye disease by ocular administration of cyclosporine A compositions were well-known in the prior art. WO’558 differs from the pending claims and originally elected species as follows: WO’558 does not explicitly (i) recite the specific ranges and formulation set forth at amended claim 1, or (ii) recite the clinical testing steps recited at claims 2, 9, 11, 13-14 (i.e., EDS, VAS, BUT, Schirmer test, ICSS). However, these differences were well-known in the prior art. As an initial matter, the specific cyclosporine A ophthalmic gel formulations required by instant claims 1, and 6-8, were prior art elements explicitly taught for the same purpose, namely the treatment of dry eye diseases. Regarding instant claims 1, 6-8, and the pharmaceutical composition of “cyclosporine A ophthalmic gel”, the composition utilized is a prior art element, as established by CN’495 as evidenced by Trans’495. CN’495 as evidenced by Trans’495 pertains to the treatment of dry eye using cyclosporine A ophthalmic gel compositions (see, e.g., CN’495 at ¶¶[0001]-[0017], claims 1-8; see Trans’495 at ¶¶[0001]-[0017], claims 1-89). Specifically, CN’495 as evidenced by Trans’495 discloses cyclosporine A ophthalmic gel compositions comprising 0.001 wt%-1 wt% of cyclosporine A; 0.1 wt%-10% nonionic surfactant; 0.01-5 wt% aqueous gel substrate; 2-30% wetting agent, water, and a pH adjusting agent in an amount sufficient to result in a final pH of 5.0-8.0, wherein the aqueous gel substrate is sodium carboxymethyl cellulose or carbomer (see, e.g., CN’495 at ¶¶[0009]-[0015], [0025]-[0035], claims 1-8; see Trans’495 at ¶¶[0009]-[0015], claims 1-810). Accordingly, all aspects and limitations of the “cyclosporine A ophthalmic gel composition” utilized in the instant claims were already known and disclosed in the prior art (see also MPEP § 2144.05(I), noting that “where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists”). In sum, in view of WO’558 and CN’495 as evidenced by Trans’495, an artisan would readily appreciate that the cyclosporine A ophthalmic gel disclosed by CN’495 as evidenced by Trans’495 was a functionally equivalent cyclosporine A ophthalmic gel suitable for use in treatments of dry eye. NCT03676335 is cited herein as a clinical trial utilized to evaluate the effectiveness of a cyclosporine A ophthalmic gel in human patients, and identifies known and routine methodologies in such clinical trials. Regarding claims 1, 4-8, 11, 13-14, and daily administration of cyclosporine A ophthalmic gel for 84 days, NCT03676335 identifies that methods of treating subjects with moderate to severe dry eye (see, e.g., NCT03676335 at 3 at §§ Official Title), by administering a CsA eye gel “0.3 g:0.15 mg” to patients, once daily, by “one drop into each eye” for 12 weeks (i.e., 84 days) (see, e.g., NCT03676335 at 5-6 at § Study Description, 7-9 at § Arms and Interventions”). Regarding instant claims 1, 2, 9, 11, 13-14, the originally elected species, and the general clinical testing steps utilized (i.e., EDS, VAS, BUT, Schirmer test, ICSS), NCT03676335 identifies that methods of treating subjects with moderate to severe dry eye by daily administration of a CsA eye gel involves monitoring and characterizing patients using an EDS score, VAS score, BUT score, Schirmer test, and corneal fluorescein staining changes score, wherein such tests are performed before, during, and after treatment (see, e.g., NCT03676335 at 9-10 at § Outcome Measures, 11-12 at §§ Criteria). NCT03676335 identifies that in such trials, it is routine to ensure patients have “moderate to severe dry eye” as defined as an EDS score more than 40 point; BUT less than 10 seconds; Schirmer test result of less than 10 mm/5 min; and “in any area” a corneal fluorescein staining changes score “more than 2 points” (see, e.g., NCT03676335 at 11-12 at §§ Criteria). In sum, NCT03676335 appears to be identical to the claimed invention, but at a minimum illustrates the routine and typical methodology utilized in clinical trials for testing and treating subjects with moderate to severe dry eye by administering a CsA eye gel. Regarding instant claim 9 and “administration “every night before the subject goes to bed”, “before” is undefined in the claim scope, and presumably includes 0.01 minutes “before” or 10+ hours “before”. Critically, WO’558 identifies that patient parameters and severity of disease impact dosing regimens, and that dosing regimens may be optimized (see, e.g., WO’558 at ¶¶[0006]-[0007], [0060]-[0061]), and that dosing frequency, including in combination with other agents, may include administering the agents at time points that vary from “about 15 minutes” to “24 hours”, to even “1 week” in time (see, e.g., WO’558 at ¶¶[0006]-[0007], [0060]-[0061]). Furthermore, NCT03676335 identifies that methods of treating subjects with moderate to severe dry eye (see, e.g., NCT03676335 at 3 at §§ Official Title), by administering a CsA eye gel “0.3 g:0.15 mg” to patients, once daily, by “one drop into each eye” for 12 weeks (i.e., 84 days) (see, e.g., NCT03676335 at 5-6 at § Study Description, 7-9 at § Arms and Interventions”). Accordingly, regarding claim 9, it has long been settled to be no more than routine experimentation for one of ordinary skill in the art to discover an optimum value of a result effective variable. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum of workable ranges by routine experimentation." Application of Aller, 220 F.2d 454, 456, 105 USPQ 233, 235-236 (C.C.P.A. 1955). "No invention is involved in discovering optimum ranges of a process by routine experimentation." Id. at 458, 105 USPQ at 236-237. The "discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art." Application of Boesch, 617 F.2d 272, 276, 205 USPQ 215, 218-219 (C.C.P.A. 1980). Since Applicant has not disclosed that the specific limitations recited in instant claim 9 provides any specific advantage or serves any any particular purpose, or otherwise solves any stated problem in the art, and the prior art teaches that dosing frequencies may vary, and that any “daily” administration is understood to be expected and predicted to successfully treat dry eye equally well, absent unexpected results, it would have been obvious for one of ordinary skill to discover the optimum workable ranges of the methods disclosed by the prior art by normal optimization procedures known in the CsA gel dry eye treatment arts. Regarding claims 11, 13-14, and “onset of efficacy”, such as an ICSS dropping by 1 point, such limitations are understood to identify if the claimed method “works as intended”, and the claimed method is presumed fully enabled for the full scope of instant claim 1. Per MPEP § 2111.04(I), “Claim scope is not limited by claim language that . . . . does not require steps to be performed, or by claim language that does not limit a claim to a particular structure”, and further states that a “whereby clause” in a claim “is not given weight when it simply expresses the intended result of a process step positively recited”. Here, these claims, at best, require ICSS testing to be reevaluated after treatment begins. However, NCT03676335 identifies that methods of treating subjects with moderate to severe dry eye by daily administration of a CsA eye gel involves monitoring and characterizing patients using an EDS score, VAS score, BUT score, Schirmer test, and corneal fluorescein staining changes score, wherein such tests are performed before, during, and after treatment (see, e.g., NCT03676335 at 9-10 at § Outcome Measures, 11-12 at §§ Criteria), including at day 14, 42, and 84 (see id). Therefore, the same active method steps are taught by the prior art, wherein results showing the treatment “works” would be obtained assuming the full scope of the prior art and instant claims are enabled. Accordingly, claims 11, 13-14, and the recitations of intended and expected results therein, are understood to be fully satisfied by methods performing the active, hand-of-man, steps of claims 1 and 1-2. Therefore, it would have been obvious to one of ordinary skill in the art, either before the effective filing date of the claimed invention (AIA ) or otherwise at the time the invention was made (pre-AIA ), to arrive at the instantly claimed invention in view of the prior art for at least the following reason(s): The invention is the simple substitution of the cyclosporine A ophthalmic gel compositions (as taught by CN’495 as evidenced by Trans’495) for the cyclosporine A ophthalmic gel composition utilized in the clinical trial of NCT03676335, wherein such simple substitution would yield predictable results as taught by WO’558 and CN’495 as evidenced by Trans’495, namely the successful treatment of moderate to severe dry eye disease in subjects (see, e.g., MPEP §§ 2143(I)(A), (B), (D), (F), (G), 2144.06(II)). Furthermore, each component merely performs its art-recognized function in combination as it does separately. No evidence of unexpected results commensurate in scope with the requirements of MPEP §§ 716, 716.01, and 716.02 have been placed on record to date. The closest existing prior art is understood to be both CN’495 as evidenced by Trans’495, and NCT03676335 (see, e.g., MPEP § 716.02(e)(II), explaining comparisons with two equally close prior art references). Furthermore, there would be a reasonable expectation of success because the prior art is presumed fully enabled (see, e.g., MPEP § 2121(I)) for all that it discloses (see, e.g., MPEP §§ 2123(I)-(II)). Furthermore, it is well-within the ordinary skill in the art to treat a known illness in a known patient population by administering, via a known route, a known formulation taught for treating such illness, using a known method for evaluating such treatment, wherein such treatment would predictably yield the expected and predicted results taught by the prior art, namely the successful treatment of dry eye in a subject. Accordingly, claims 1-2, 4-11, and 13-14 are rejected. Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. NCT0454188811, record V1 as published September 7, 2020, is directed to a Phase 3 clinical trial, wherein the patient population, drug compositions tested, and clinical steps appear identical to those discussed above for NCT03676335. Peng et al.12 (“Peng2021”) has been previously discussed on record in the Requirement (see, e.g., Requirement mailed 7/08/2026 at 5-6 at bridging ¶), and that discussion is incorporated herein. Examiner notes that Applicant suggests that the formulation of Peng2021 “does not contain any surfactants” (see, e.g., Reply filed 9/07/2026 at 6 at final ¶). This statement is misleading and factually incorrect because it ignores the following qualifier in the quoted sentence, namely “the formulation does not contain any surfactants or preservatives that might counteract the beneficial cyclosporine effects in other formulations” (see, e.g., Peng2021 at 625 at col I). Accordingly, the tested formulation does not, per se, exclude all surfactants or preservatives, only those “that might counteract the beneficial cyclosporine effects in other formulations”. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RANDALL L BEANE whose telephone number is (571)270-3457. The examiner can normally be reached Mon.-Fri., 7 AM to 2 PM ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G. Garyu can be reached at (571) 270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RANDALL L BEANE/ Primary Examiner, Art Unit 1654 1 Example 7, wherein human subjects with "moderate to severe tear deficiency" (defined per ¶¶[00201]-[00207]) were administered 0.3g:0.15 mg cyclosporine gel once daily for 84±6 days following a wash out period of 14 days (understood to be 0.05% per ¶[00l75] and [00191]), wherein VAS score, BUT determination, corneal staining, ICSS scoring, Schirmer test, etc. is performed (see, e.g., Spec. filed 4/25/2024 at ¶¶[00l76]-[00522]; see esp. id. at ¶¶[00189], [00193], [00260], [00285]-[00290]). 2 I.e., any composition falling within the genus of compositions comprising 0.001-1 wt% cyclosporine A; 0.1-10 wt% nonionic surfactant; 0.01-5 wt% of either sodium carboxylmethyl cellulose or carbomer; 2-30 wt% wetting agent; water; and a pH adjusting agent in an amount sufficient to result in a final pH of 5.0-8.0, are understood to read upon the originally elected subgenus of patentably indistinct species. This is reasonable because [0067] states that such compounds were utilized in “the methods disclosed herein”, and Applicant did not further identify a more specific species of composition (see Reply filed 9/07/2026 at 5-6). 3 This ratio is not explained, and Applicant indicated that the elected species read upon instant claim 8, which recites that the administered “effective amount” of cyclosporine A is “about 0.025 mg”, which does not correspond to either number in the ratio. 4 Machine Translation of CN103735495 to English, Translated by Patent Translate Espacenet.org on 10/20/2026, 98 Pages. 5 see, e.g., MPEP § 2111.04(I), “Claim scope is not limited by claim language that . . . . does not require steps to be performed, or by claim language that does not limit a claim to a particular structure”, and further states that a “whereby clause” in a claim “is not given weight when it simply expresses the intended result of a process step positively recited”. 6 Cited in Requirement mailed 7/08/2026. 7 Machine Translation of CN103735495 to English, Translated by Patent Translate Espacenet.org on 10/20/2026, 105 Pages. 8 NCT03676335, Clinical Trial “Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye”, Publication date May 6, 2020; attached as 15 page pdf, also available at https://clinicaltrials.gov/study/NCT03676335?tab=history&a=3#version-content-panel (last visited 10/21/2026). 9 Note that the translation refers to an image, which is shown at CN’495 at claim 1 and ¶[0009]. 10 Note that the translation refers to an image, which is shown at CN’495 at claim 1 and ¶[0009]. 11 NCT04541888, Clinical Trial “Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye”, Publication date September 7, 2020; attached as 15 page pdf, also available at https://clinicaltrials.gov/study/NCT04541888?tab=history&a=1#version-content-panel (last visited 10/21/2026). 12 Peng et al., Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study. Clin Ther. 2021 Mar;43(3):613-628. doi: 10.1016/j.clinthera.2020.12.023. Epub 2021 Feb 3. PMID: 33546885; hereafter "Peng2021"; cited in Requirement mailed 7/08/2026.
Read full office action

Prosecution Timeline

Apr 25, 2024
Application Filed
Dec 17, 2024
Response after Non-Final Action
Oct 23, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773457
IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS
5y 7m to grant Granted Oct 27, 2026
Patent 12773443
Insulin Derivative
4y 4m to grant Granted Oct 27, 2026
Patent 12741989
COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS
4y 3m to grant Granted Sep 22, 2026
Patent 12734211
USE OF POLYPEPTIDE IN DRUG FOR PREVENTING AND TREATING PNEUMONIA
3y 6m to grant Granted Sep 15, 2026
Patent 12715897
INHIBITORS OF HUMAN EPIDIDYMUS PROTEIN 4
3y 10m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
33%
Grant Probability
69%
With Interview (+36.3%)
3y 3m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 459 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month